Replies to post #9759 on BioCurex, Inc.(fka BOCX)

[opportunityknocking]

Mysscat, I truly believe that they don't know what to do with it. Abbott doesn't want to shoot themselves in the foot and eliminate other cancer diagnostic tests which in turn would reduce their monetization. There will become a moral issue as to what direction this will go, because we all know that this test alone would eliminate most unnecessary biopsies, surgery as well as therapy. I suggest that Biocurex approach this at a governmental level, speaking with government officials, starting with Canada, and target countries that are practicing socialized medicine. This would be accepted with open arms, and the cost savings to their medical system would be hard to dispute. Then I feel that our country and all others would also be hard-pressed to follow suit.
The board has to close the deal with other licensees soon or we will lose all the momentum garnered by the recent meeting. Abbott has too many other licensing deals to focus soley on us. I am up in arms at the waste of money and the amount of share dilution that is blown on penny stock news letters. I feel it is time to start asking the necessary questions as to why we are still unnoticed at this stage of the game. I propose we all put together a letter FROM THE SHAREHOLDERS to the board of Biocurex and have them address our questions and concerns. We deserve better exposure than penny stock newsletters. Why are they so shy and not at least attempt national media exposure. If they signed another lincensee Abbott is forced to move forward. My single most important question is why are we not presenting at EVERY cancer meeting?
I am not proposing that we attack the board, but the voices of many speak much loader than the voice of one. Let's draft a letter from all who have the best interests for the company at heart and let's continue the momentum. It is unacceptable to me that no one even knows that this technology exists.

[oraclewizard77]

I think its up to Abbott since applying for FDA approval is a long and expensive process.

The good news as I see it was the joint presentation with Abbott. More good news will be any other payments by Abbott or another license with a different vendor.

They may also want to talk to the FDA on what test data that they need to collect to get FDA approval and work on a large enough test sample to make the procedure worth it.

Obviously like any drug that gets FDA approval and therefore increases the stock price, news of final FDA approval could get us above the $ 10/sh range, but it still looks like a few years off from here.